Last $38.35 USD
Change Today 0.00 / 0.00%
Volume 0.0
ESALF On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
OTC US
Frankfurt
As of 8:10 PM 12/18/14 All times are local (Market data is delayed by at least 15 minutes).

eisai co ltd (ESALF) Snapshot

Open
$38.35
Previous Close
$38.35
Day High
$38.35
Day Low
$38.35
52 Week High
08/15/14 - $42.10
52 Week Low
12/1/14 - $35.85
Market Cap
11.4B
Average Volume 10 Days
28.5
EPS TTM
--
Shares Outstanding
296.6M
EX-Date
03/27/15
P/E TM
--
Dividend
$157.08
Dividend Yield
3.71%
Current Stock Chart for EISAI CO LTD (ESALF)

Related News

No related news articles were found.

eisai co ltd (ESALF) Related Businessweek News

No Related Businessweek News Found

eisai co ltd (ESALF) Details

Eisai Co., Ltd. manufactures and sells pharmaceutical products worldwide. The company offers oncology-related products, such as Halaven, an anticancer agent; Aloxi, an antiemetic agent; and Fragmin, an injectable anticlotting agent, as well as Symbenda/Treakisym, a treatment for low-grade non-Hodgkin's lymphoma and other types of lymphatic cancer. It also provides Aricept, an anti-Alzheimer's agent; Pariet/AcipHex, a proton-pump inhibitor; and Humira, a human anti-TNF-a monoclonal antibody. In addition, the company offers epilepsy products comprising Zonegran, Zebinix, and Fycompa, which are antiepileptic agents; and Inovelon/BANZEL for the treatment of Lennox-Gastaut syndrome, as well as consumer healthcare (over-the-counter) products, which include vitamin B2 preparation Chocola BB Plus. Further, it provides Methycobal, a peripheral neuropathy treatment; Warfarin, an oral anticoagulant; Actonel, an osteoporosis treatment; Selbex for the treatment of gastritis/gastric ulcer; BELVIQ, an antiobesity agent; Stronger Neo-Minophagen C/Glycyron tablets for liver disease/allergic disease treatment; Lyrica, a treatment for postherpetic neuralgia; and Lunesta, a treatment for insomnia. Additionally, the company is involved in the research and development of various products under the areas of oncology, vascular and immunological reaction, gastrointestinal and hepatic disorders, and neurology. It has strategic partnerships with Quintiles Inc.; SFJ Pharma Ltd.; Biogen Idec, Inc.; BioArctic Neuroscience AB; FORMA Therapeutics, Inc.; Epizyme, Inc.; PRISM BioLab Co., Ltd.; and Verastem, Inc. for the discovery and development of various products. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.

10,419 Employees
Last Reported Date: 06/20/14
Founded in 1941

eisai co ltd (ESALF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

eisai co ltd (ESALF) Key Developments

Eisai Co., Ltd. Presents New Phase III Data at the American Epilepsy Society Annual Meeting in Seattle, Washington

Eisai Co., Ltd. presents new Phase III data at the American Epilepsy Society (AES) Annual Meeting in Seattle, Washington, of Fycompa® (perampanel) as adjunctive therapy for primary generalised tonic-clonic seizures (PGTC). Perampanel is currently indicated for the adjunctive treatment of partial onset seizures, with or without secondarily generalised seizures, in patients with epilepsy aged 12 years and older. Perampanel is the only licensed anti-epileptic drug (AED) to selectively target AMPA receptors, a protein in the brain which plays a critical role in the spread of seizures. This mechanism of action is different to all other, currently available AEDs. In addition, perampanel has the added benefit of convenient, once-daily dosing at bedtime and, significantly, is the only new-generation partial epilepsy treatment approved to treat adolescents (>12 years) with epilepsy from launch. The results from study 332 demonstrate that perampanel significantly reduces primary generalised tonic-clonic seizure frequency and improves responder rates (=50% reduction in seizure frequency per 28 days in the maintenance period, relative to baseline), the study's two primary outcome measures, when compared to placebo. The study showed that adjunctive treatment with perampanel improved seizure control in people with idiopathic generalised epilepsy aged 12 years and over who were living with inadequately controlled primary generalised tonic-clonic seizures. 30.9% using perampanel were free of tonic-clonic seizures and it was well tolerated with a safety profile similar to refractory partial-onset seizures. Discovered and developed by Eisai in Europe and Japan, perampanel is manufactured in the UK and was approved by the European Commission on 23 July 2012. Perampanel is now approved in more than 35 countries worldwide. Eisai submitted a Marketing Authorisation Application to the European Commission in August 2014 for an indication expansion for perampanel to include the adjunctive treatment of PGTC seizures in people with epilepsy.

Eisai Co., Ltd. Establishes Holding Company Eisai China Holdings Ltd. in China

Eisai Co., Ltd. announced that it has established a holding company Eisai China Holdings Ltd. in Suzhou, Jiangsu Province, China. Eisai China Holdings Ltd. is a subsidiary of Eisai Asia Regional Services Pte. Ltd. which is Eisai's representative subsidiary for Asia located in Singapore. With the establishment of this new company, Eisai China Holdings Ltd. will integrate the Chinese domestic subsidiaries Eisai China Inc. and Eisai (Suzhou) Trading Co. Ltd., strengthen various functions including accounting, legal and compliance, and also create a flexible capital transfer system to respond to capital demands, in order to optimize the management of business in China. It is expected to achieve strong double digit growth into the future. Through the establishment of Eisai China Holdings Ltd., Eisai plans to further enhance its pharmaceutical production, sales and supply systems in China, and through the stable supply of high quality pharmaceutical products together with the provision of accurate information, strives to fulfill the diverse needs of patients and their families in China.

Eisai Co., Ltd. Opens New Parenteral Facility in China

Eisai Co., Ltd. announced that construction of a new production facility has been completed in Suzhou, Jiangsu, China. The new facility was built on an approximately 134,000 sq m lot in the Suzhou Industrial Park which was newly purchased by Eisai for the construction. It stands two floors aboveground with a total floor space of approximately 3,300 sq m. Serving as the company's new base for parenteral manufacturing, the new facility is initially equipped with a production line for Methycobal injection that has the capacity to manufacture an approximate maximum of 60 million ampoules per year. Furthermore, the company intends to expand the role of the new facility in the future to function as a global supply center of injection products for a wider range of markets including the rest of Asia and Latin America.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ESALF:US $38.35 USD 0.00

ESALF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Almirall SA €14.13 EUR +0.13
Cubist Pharmaceuticals Inc $100.30 USD +0.01
Ono Pharmaceutical Co Ltd ¥11,050 JPY +260.00
Salix Pharmaceuticals Ltd $118.09 USD +3.17
Santen Pharmaceutical Co Ltd ¥6,510 JPY 0.00
View Industry Companies
 

Industry Analysis

ESALF

Industry Average

Valuation ESALF Industry Range
Price/Earnings 78.1x
Price/Sales 2.2x
Price/Book 2.3x
Price/Cash Flow 81.1x
TEV/Sales 1.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EISAI CO LTD, please visit www.eisai.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.